A post-hoc analysis of a trial of naproxen and rofecoxib for mild-to-moderate AD demonstrated that those who responded favorably exhibited a distinct plasma neuroinflammatory profile (TNF-α, CRP, IL-6 and IL-10) [150]. This evidence concerns the gene IL10 and Alzheimer disease.